HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Court Suggests Critics Ask Congress To Change FDA's GRAS Rule – Same For NDI Notifications?

Executive Summary

Federal judge suggests consumer health and environmental advocacy groups made strong arguments about potential for unsafe ingredients in foods available in the US through the self-GRAS process, but FDA adopted and exercises the rule entirely in line with congressional intent of the authorizing legislation.

You may also be interested in...



Senate Bill Would Categorize Food Ingredients As Old And OK, Or New And Needing Approval

Bill would establish cutoff date for food ingredients to be made available as GRAS and not subject to food additive petition requirement. Also proposes establishing a FDA office for ongoing reviews of existing food additives and GRAS substances.

US Supplement Industry Capitol Hill Champion, Pivotal Drug Legislation Author Orrin Hatch Dies

DSHEA, legislation Congress passed in 1994 establishing framework for FDA’s oversight of supplement manufacturing and marketing, doesn’t bear Hatch’s name. But in US consumer health products industry, his name is probably more frequently linked with DSHEA than with pivotal drug legislation he co-authored.

FDA's Latest Hornedine Find Is On Texas Firm’s Supplement Labels During Website Inspection

Hornedine isn’t an “old” dietary ingredient exempt from pre-market notification with proof its safety because it wasn’t available in the US food supply before October 1994. "T

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel